- Home
- UOKA vs GLMD Comparison
UOKA vs GLMD Comparison
Compare UOKA & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UOKA
- GLMD
- Stock Information
- Founded
- UOKA 2002
- GLMD 2000
- Country
- UOKA United Kingdom
- GLMD Israel
- Employees
- UOKA N/A
- GLMD N/A
- Industry
- UOKA
- GLMD Biotechnology: Pharmaceutical Preparations
- Sector
- UOKA
- GLMD Health Care
- Exchange
- UOKA NYSE
- GLMD Nasdaq
- Market Cap
- UOKA 2.7M
- GLMD 3.0M
- IPO Year
- UOKA N/A
- GLMD 2014
- Fundamental
- Price
- UOKA $2.40
- GLMD $1.81
- Analyst Decision
- UOKA
- GLMD Hold
- Analyst Count
- UOKA 0
- GLMD 1
- Target Price
- UOKA N/A
- GLMD N/A
- AVG Volume (30 Days)
- UOKA 128.0K
- GLMD 364.3K
- Earning Date
- UOKA 08-16-2025
- GLMD 05-22-2025
- Dividend Yield
- UOKA N/A
- GLMD N/A
- EPS Growth
- UOKA N/A
- GLMD N/A
- EPS
- UOKA N/A
- GLMD N/A
- Revenue
- UOKA $48,375.00
- GLMD N/A
- Revenue This Year
- UOKA N/A
- GLMD N/A
- Revenue Next Year
- UOKA N/A
- GLMD N/A
- P/E Ratio
- UOKA N/A
- GLMD N/A
- Revenue Growth
- UOKA N/A
- GLMD N/A
- 52 Week Low
- UOKA $1.98
- GLMD $1.15
- 52 Week High
- UOKA $42.50
- GLMD $23.80
- Technical
- Relative Strength Index (RSI)
- UOKA N/A
- GLMD 61.13
- Support Level
- UOKA N/A
- GLMD $1.63
- Resistance Level
- UOKA N/A
- GLMD $1.94
- Average True Range (ATR)
- UOKA 0.00
- GLMD 0.12
- MACD
- UOKA 0.00
- GLMD 0.01
- Stochastic Oscillator
- UOKA 0.00
- GLMD 69.77
About UOKA MDJM LTD
MDJM Ltd is engaged in providing real estate agency services to its real estate developer clients, and provides, on an as-needed basis, real estate consulting services and independent training services. The company generates all of its revenue from Hotel income. The company derives a majority of its revenue from the United Kingdom.
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.